Wet Age-related Macular Degeneration Clinical Trial
Official title:
Phase I Clinical Trial of Recombinant Anti-VEGF Human Monoclonal Antibody in the Treatment of Wet Age-related Macular Degeneration
Multicenter study to evaluate the safety and tolerability in patients with wet Age-related macular degeneration (wAMD) treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody
According to the results of preclinical pharmacological research and clinical application of bevacizumab in ophthalmology Case, 601 will be developed as a drug candidate for the treatment of ocular diseases such as wAMD .Observe the safety and tolerability of the single and multiple doses of 601 in wAMD patients; study the pharmacokinetic characteristics of single and multiple doses of 601, Observe the Preliminary efficacy of 601 multiple injections with different doses in the treatment of patients with wAMD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00138632 -
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
| Terminated |
NCT04594681 -
A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
|
Phase 1 | |
| Completed |
NCT03585556 -
AAVCAGsCD59 for the Treatment of Wet AMD
|
Phase 1 | |
| Completed |
NCT03362190 -
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
|
Phase 2 | |
| Not yet recruiting |
NCT04564937 -
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04504123 -
MMP-9 Inhibition for Recalcitrant Wet AMD
|
Phase 2 | |
| Terminated |
NCT02005133 -
A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics
|
N/A | |
| Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
| Completed |
NCT03748784 -
ADVM-022 Intravitreal Gene Therapy for Wet AMD
|
Phase 1 | |
| Completed |
NCT04685369 -
Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
|
||
| Enrolling by invitation |
NCT04932980 -
Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
|
N/A | |
| Recruiting |
NCT05297292 -
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
|
Phase 2/Phase 3 | |
| Completed |
NCT03939767 -
Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
|
||
| Completed |
NCT03066258 -
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
|
Phase 1/Phase 2 | |
| Terminated |
NCT01086761 -
Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration
|
Phase 1 | |
| Recruiting |
NCT05727397 -
Efficacy and Safety of RC28-E Versus Aflibercept
|
Phase 3 | |
| Completed |
NCT04884399 -
Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD
|
Phase 1 | |
| Withdrawn |
NCT01339949 -
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
|
N/A | |
| Terminated |
NCT00139282 -
A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration
|
Phase 3 | |
| Completed |
NCT04964089 -
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
|
Phase 3 |